Johnson & Johnson Launches Surgical Robot, but Analysts Doubt It Will Significantly Impact Intuitive Surgical
Johnson & Johnson (JNJ) has launched its Ottava surgical robot in the U.S., marking its first entry into soft-tissue surgery. The device received FDA De Novo authorization and is designed to reduce floor space requirements by half compared to traditional robotic systems like those from Intuitive Surgical (ISRG). Despite this development, analysts remain skeptical about J&J's ability to challenge ISRG’s dominance in the market. Intuitive Surgical continues to hold a strong position due to its entrenched relationships with surgeons and hospital workflows. According to analyst Robbie Marcus of J.P. Morgan, most doctors still prefer Intuitive’s da Vinci system because it is deeply integrated into existing procedures and training programs. Switching platforms requires retraining entire surgical teams, which poses a significant barrier for competitors like Medtronic's Hugo robot. Ottava offers advantages in design but faces the same uphill battle as other entrants: convincing hospitals to adopt new systems when they already own Intuitive’s equipment. While J&J is well-positioned with its brand and resources, analysts believe it will take more than product innovation alone for Ottava to make a meaningful dent in ISRG's market share.
Topics: FDA authorization Intuitive Surgical (ISRG) Johnson & Johnson (JNJ) robotic surgery